Literature DB >> 15042369

Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients.

Manuel Montesinos-Rongen1, Razvan Besleaga, Susanne Heinsohn, Reiner Siebert, Hartmut Kabisch, Otmar D Wiestler, Martina Deckert.   

Abstract

Simian virus 40 (SV40) is known to induce primary brain tumors and lymphomas in animal models. Recently, it was also associated with the pathogenesis of human non-Hodgkin's lymphomas. In the present study, we investigated primary central nervous system lymphomas (PCNSL), a defined subgroup of diffuse large B-cell lymphoma confined to the central nervous system, for the presence of SV40 DNA. Frozen tissue samples of 23 PCNSL derived from human immunodeficiency virus-negative patients were analyzed by two different, fully nested polymerase chain reaction protocols. SV40 DNA sequences could not be detected in any of these samples. Thus, SV40 can be added to the list of viruses that have already been excluded as pathogenetically relevant cofactors in PCNSL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15042369     DOI: 10.1007/s00428-004-1001-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  10 in total

1.  Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment.

Authors:  M Montesinos-Rongen; R Küppers; D Schlüter; T Spieker; D Van Roost; C Schaller; G Reifenberger; O D Wiestler; M Deckert-Schlüter
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma.

Authors:  P Rizzo; M Carbone; S G Fisher; C Matker; L J Swinnen; A Powers; I Di Resta; S Alkan; H I Pass; R I Fisher
Journal:  Chest       Date:  1999-12       Impact factor: 9.410

3.  Human herpesvirus-6 and Epstein-Barr virus genome in primary cerebral lymphomas.

Authors:  W Paulus; K Jellinger; C Hallas; G Ott; H K Müller-Hermelink
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

4.  Human herpes virus-8 is not associated with primary central nervous system lymphoma in HIV-negative patients.

Authors:  M Montesinos-Rongen; V H Hans; A M Eis-Hübinger; M Prinz; C Schaller; D Van Roost; A Aguzzi; O D Wiestler; M Deckert
Journal:  Acta Neuropathol       Date:  2001-11       Impact factor: 17.088

5.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity.

Authors:  A R Thompsett; D W Ellison; F K Stevenson; D Zhu
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

6.  Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease.

Authors:  M Montesinos-Rongen; A Roers; R Küppers; K Rajewsky; M L Hansmann
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

7.  Presence of simian virus 40 DNA sequences in human lymphomas.

Authors:  Narayan Shivapurkar; Kenichi Harada; Jyotsna Reddy; Richard H Scheuermann; Yin Xu; Robert W McKenna; Sara Milchgrub; Steven H Kroft; Ziding Feng; Adi F Gazdar
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

8.  Association between simian virus 40 and non-Hodgkin lymphoma.

Authors:  Regis A Vilchez; Charles R Madden; Claudia A Kozinetz; Steven J Halvorson; Zoe S White; Jeffrey L Jorgensen; Chris J Finch; Janet S Butel
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

9.  Vasopressin-SV40 T antigen expression in transgenic mice induces brain tumor and lymphoma.

Authors:  Jeong Woong Lee; Jun Hong Park; Kil Soo Kim; Eun Ju Lee; Myoung Ok Kim; Sung Hyun Kim; Seong Whan Jeong; Chul Woo Kim; Ho Joon Lee; Kyung Sun Kang; Kyu Tae Chang; Byung Hwa Hyun; Zae Young Ryoo
Journal:  Biochem Biophys Res Commun       Date:  2003-03-21       Impact factor: 3.575

10.  Association between simian virus 40 DNA and lymphoma in the United kingdom.

Authors:  Jane MacKenzie; Katherine S Wilson; Jacqueline Perry; Alice Gallagher; Ruth F Jarrett
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

  10 in total
  6 in total

Review 1.  Simian virus 40 transformation, malignant mesothelioma and brain tumors.

Authors:  Fang Qi; Michele Carbone; Haining Yang; Giovanni Gaudino
Journal:  Expert Rev Respir Med       Date:  2011-10       Impact factor: 3.772

2.  Variable frequency of polyomavirus SV40 and herpesvirus EBV in lymphomas from two different urban population groups in Houston, TX.

Authors:  Sonia Toracchio; Claudia A Kozinetz; Deanna E Killen; Andrea M Sheehan; Eugenio I Banez; Michael M Ittmann; Vojtech Sroller; Janet S Butel
Journal:  J Clin Virol       Date:  2009-07-23       Impact factor: 3.168

Review 3.  Insights into the biology of primary central nervous system lymphoma.

Authors:  Maciej M Mrugala; James L Rubenstein; Maurilio Ponzoni; Tracy T Batchelor
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

4.  Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40.

Authors:  Katharina Leithner; Andreas Leithner; Heimo Clar; Andreas Weinhaeusel; Roman Radl; Peter Krippl; Peter Rehak; Reinhard Windhager; Oskar A Haas; Horst Olschewski
Journal:  Orphanet J Rare Dis       Date:  2006-11-07       Impact factor: 4.123

Review 5.  Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features.

Authors:  Marietya I S Lauw; Calixto-Hope G Lucas; Robert S Ohgami; Kwun Wah Wen
Journal:  Diagnostics (Basel)       Date:  2020-12-11

6.  The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.

Authors:  Manuel Montesinos-Rongen; Monica Terrao; Caroline May; Katrin Marcus; Ingmar Blümcke; Martin Hellmich; Ralf Küppers; Anna Brunn; Martina Deckert
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.